Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986207 with Nivolumab and Ipilimumab in Stage IV NSCLC
NCT05005273Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing BMS-986207 + Nivo + Ipi with Placebo + Nivo + Ipi (2 arms). Primary endpoint: Progression Free Survival by BICR at 2.3 months. Started Oct 2022; status: completed.
02
Drugs
BMS-986207
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05005273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005273.